That consumers are engaged with their own healthcare more now than ever before might make it all too easy to overlook how deeply their modes of engagement differ from one another. It sounds logical to assume that general engagement with information would reliably predict eng … Read More »

Download infographic now http://bit.ly/LMS-ICON Establishing a training plan for all site and study staff is standard procedure for every clinical study. For regulatory compliance, sponsors need to track and provide documented evidence that allocated training has been comple … Read More »

True patient-centricity—one of the biggest healthcare buzzwords for some time—now calls for accessing the other people central to the patient: their caregivers. But these personalities, who are not just present throughout the patient experience but display a range of emotion … Read More »

Download now http://bit.ly/CDISC-ICON This recent case study by ICON outlines a project for a big pharma company. It provides advice and demonstrates the expertise needed to deliver a seamless solution for a multiple indication compound, which included 36 legacy studies. Key … Read More »

As part of its leading-edge trends reports, Syneos HealthTM has released a comprehensive analysis of currents in healthcare and what will be their tidal impact on the industry landscape. As the only end-to-end biopharmaceuticals solutions organization, Syneos Health consulte … Read More »

Instant download of paper http://bit.ly/DrugSafetyRWE A renewed focus on drug safety has emerged with the increased number of approved drugs, greater availability of information, and more direct involvement of patients in their treatments. Evidera’s latest paper covers the n … Read More »

Instant download of paper http://bit.ly/patient-perspective Have you been told by the U.S. Food and Drug Administration (FDA) to include the patient’s perspective about treatment benefit in your drug development program? If so, were you prepared to provide it? Evidera’s rece … Read More »

Our latest issue’s SpeakOut article outlines how a Cross-Trial SaaS Solution can improve your safety notifications process. Topics covered include: Cost Reduction Time Savings Greater Audit Compliance and Increased Transparency Reduced Liability The Risk of Waiting If this i … Read More »

Evidera recently wrote a paper comparing two common types of NMA approaches to reimbursement for treatments. When considering potential reimbursement of a new treatment, Health Technology Assessment (HTA) bodies worldwide need to evaluate how the product’s clinical effects c … Read More »

Have you ever hoped there was a better way to gain insights into the physicians your reps are calling on? Even no-see docs? A promising new technology offers this very solution to a nagging problem. IQcentRx, LLC, recently announced the introduction of Call-IQ, a sales force … Read More »

Evidera recently wrote an article on utilizing Machine Learning and Big Data to achieve better results. This article reviews applications that increase efficiency and allow more convincing value demonstration, broadly following a product’s lifecycle from drug discovery to dr … Read More »

Aptus Health has provided a case study on a successful Market Access Pull-Through Program. Here is a summary of the document. To capitalize on its brands’ favorable formulary positioning, we helped our client develop a Market Access Pull-Through Program (MAPP) powered by Apt … Read More »

In this white paper, you will learn how clinical trial simulation (CTS) can support early market access planning by predicting a range of feasible trial results of a new treatment that can be fed into an economic model, making it possible to anticipate challenges to the econ … Read More »

Specialty medications, which have emerged as important new treatment options for complex diseases like oncology, rheumatology and neurology, now represent approximately 50% of the overall pharmaceutical market spend, according to the report, Medicine Use and Spending in the … Read More »

PRA has recently released a white paper about technology’s effects on rare disease research. Approximately 7,000 rare diseases affect an estimated 350 million people worldwide, and with diagnostic advances, new diseases are discovered every day. Although the number of clinic … Read More »

PRA has written a new white paper on the considerations for planning and conducting global rare disease clinical trials. Rare disease trials are inherently designed to include fewer patients, are often longer in duration, and more frequently terminated than trials in more co … Read More »

Comparative clinical benefit assessments are at the core of Health Technology Assessments (HTAs) in Europe. HTAs are a multi-disciplinary process considering input and evidence from medical, social, and economic sources. They are used to inform the design of health policies … Read More »

Finding a home for your biopharmaceutical company’s new orphan drug doesn’t just happen after it is FDA approved. The successful commercialization of your promising new drug requires a focused and well-planned distribution model. But first, some background. Orphan drugs trea … Read More »

PRA has written a new white paper on conducting clinical trials with adolescents, specifically children with impaired mental capacity. In the majority of clinical trials we undertake, the consent process is fairly straightforward; however, we do conduct studies in patients w … Read More »

By Jim Datin, President and CEO, BioAgilytix Bioanalytical outsourcing has changed dramatically in the past 30 years, which isn’t surprising when you consider how our economy, the healthcare market, technology, and drugs themselves have changed in that same period. In order … Read More »